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Introduction
Hearing impairment is the most common sensory dis-
order worldwide. It affects approximately 3% of the
population. When present from birth it can affect a
child’s development, not only linguistically but also in
ambulation and the formation of social relationships. In
cases of postlingual deafness, affected individuals often
suffer from social isolation and the inability to adapt to a
noisy environment.
Many etiologies have been identified for hearing im-
pairment, both environmental and genetic. Environmen-
tal causes can range from neonatal insults, such as pre-
maturity, jaundice, or prenatal infection and iatrogenic
causes. The genetic etiologies can be inherited as either
syndromic or nonsyndromic forms, and have a spectrum
of inheritance patterns. Currently, genetics may account
for approximately 50% of all childhood deafness. Re-
cent research has focused on identifying the genetic
causes that may be important not only to the patient but
also in assessing the success of certain therapies such as
cochlear implants.
In the past, establishing a genetic etiology based on
the clinical presentation has only been possible for syn-
dromic deafness, whereby patients present with classic
audiologic and systemic manifestations. However, a
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great challenge exists in assessing a genetic cause for pa-
tients who present with nonsyndromic hearing loss. Clas-
sically, all that may be untangled at the time of presenta-
tion of the inheritance pattern of the deafness. For exam-
ple, autosomal recessive deafness typically presents as a
congenital or prelingual, severe to profound deafness af-
fecting all frequencies while autosomal dominant deaf-
ness is more often postlingual with variations in severity
and affected frequencies. There are of course exceptions
that make particular genetic causes easier to identify.
This review highlights phenotypes associated with non-
syndromic deafness in an effort to help evaluation of pa-
tients and to establish a role for genetic testing in some
of these patients. The impact of genomic advances for
comprehensive genetic testing and gene discovery in he-
reditary hearing loss is also discussed.
Epidemiology of Non-Syndromic Loss
Hearing loss affects approximately 70 million people
worldwide. 50-60% of these cases have a genetic etiolo-
gy; the remaining 40-50% of cases are attributed to envi-
ronmental factors, such as ototoxic drugs, prematurity, or
trauma. However, as public health awareness is im-
proved, environmental factors are contributing less to the
etiology of deafness and the relative proportion of genet-
ic hearing loss is increasing[66]. Approximately, one in ev-
ery 1000 children has some form of prelingual hearing
impairment[74], and 1 in 2000 is caused by a genetic muta-
tion. 30% of cases of prelingual deafness are classified
as syndromic; the remainders are non-syndromic.
The inheritance of nonsyndromic deafness depends up-
on the time of onset. Prelingual types have a predomi-
nantly (80% ) autosomal recessive inheritance, although
20% are inherited in an autosomal dominant pattern, 1%
are X-linked, and less than 1% are mitochondrial inheri-
tance[74]. Postlingual types are most commonly autoso-
mal dominant, whereas autosomal recessive forms are
rare but more severe.
Non-syndromic deafness is a paradigm of genetic het-
erogeneity. To date, 69 genes have been identified (24
for dominant and 40 for recessive deafness; Hereditary
Hearing Loss Homepage, June, 2013) with new genes be-
ing discovered at a rapid pace. This review summarizes
the most relevant information about different genes asso-
ciated with nonsyndromic deafness along with their pro-
posed molecular function in the auditory system, and de-
scribes the phenotypes that have been correlated to spe-
cific genotypes.
Nonsyndromic loci are being discovered at an unbe-
lievable pace. Currently, 145 loci have been discovered-
57 for autosomal dominant, 77 autosomal recessive, 8
X-linked, 2 modifier and 1 Y linked deafness. Some of
these loci share a common gene, while others have un-
known genes. Nonetheless, each type of inheritance has
a generalized clinical picture that applies to most of the
genes or loci. Autosomal recessive deafness tend to
cause severe, prelingual deafness involving all frequen-
cies; autosomal dominant loci are typically less severe,
postlingual, with hearing loss that can vary by frequen-
cy; lastly, X-linked loci affect males more severely than
females and can impair all frequencies or only high fre-
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quencies (Table 1).
Genotype-Phenotype Corelations of Com-
mon Forms of Non-Syndromic Hearing
Loss
Most gene discoveries are based on a single family
where deafness has been inherited. While nonsyndromic
genes only affect hearing, their expression is not neces-
sarily limited to the inner ear. It may be that the inner
ear is simply more sensitive to the identified mutation.
Genes can be classified by their molecular function.
This review will classify the genes by the following func-
tions: Homeostasis, Hair Cell Structure, Transcription
Factors, Cytokinesis, Extracellular Matrix, Mitochondri-
al and Other/Unknown.
Cochlear Ionic Homeostasis
Homeostasis is maintained by a number of mecha-
nisms whereby the flow of molecules into and out of a
cell is regulated. In the inner ear, a number of channels
have been found to be critical to maintaining homeosta-
sis. These include gap junctions, ion channels, and tight
junctions. In addition, genes coding for neuronal synaps-
es and integral membrane proteins have also been identi-
fied as key components of homeostasis.
Gap Junctions
Gap junctions are composed of transmembrane pro-
teins called connexins. Six connexins combine to form a
hemi-channel known as a connexon. When two connex-
ons are joined, a gap junction is created. Within the inner
ear, gap junctions allow the recycling of potassium ions
back into the endolymph during mechanosensory trans-
duction process. Mutations in connexins that alter the
structure and/or function of the gap junctions thereby re-
sult in various forms of deafness. Currently, 3 genes
have been identified which code for connexins, and
which when mutated result in nonsyndromic hearing
loss: GJB2, GJB3, and GJB6[91] whereas GJB4 and GJA
were found to associated with hearing loss, with unclear
mechanisms.
GJB2 (DFNB1A, DFNA3A)
Gap junction protein beta 2 gene (GJB2) codes for con-
nexin 26 and is located at chromosome 13 q11-12. GJB2
contribute to up to 50% of recessive nonsyndromic hear-
ing loss[22]. While more than 100 mutations have been re-
ported, the most common mutation in Europe, North
America, and the Mediterranean is a deletion of 6 gua-
nine nucleotides referred to as 35delG. Other prevalent
mutations include the 167delT in the Ashkenazi Jewish
population, 235delC in the Asian population and V37I in
the Taiwanese population. The Indonesian population ap-
pears to lack GJB2 mutations in their deaf community[110].
The recessive form, DFNB1, usually presents as a stable,
severe to profound hearing loss; however, progression
has been reported. While there is phenotypic variation
across GJB2 genotypes, patients with the 35delG muta-
tion tend to have the most severe form of hearing im-
pairmnt[110]. Onset is almost always prelingual, but not
necessarily congenital[21]. In fact, hearing may be normal
at birth but progress rapidly during infancy[34]. Children
have been diagnosed as late as 60 months due to nonpen-
etrance at birth[79]. Thus, newborn screening tests may
not always be reliable for detection and a role for genetic
screening is recommended.TheV37I is another GJB2 vari-
ant that is frequently found in East Asian populations and
is considered as a genetic risk-indicator of postnatal per-
manent childhood hearing impairment and is associated
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with mild to moderate hearing loss [138.
The autosomal dominant form, DFNA3, typically pres-
ents during childhood as a progressive, moderate to se-
vere hearing impairment affecting mostly high frequen-
cies. It progresses to involve middle frequencies by mid-
dle age[21]. As with recessive forms of GJB2, phenotypic
variability is present in terms of the severity and evolu-
tion of hearing impairment[28]. DFNA3 has been associat-
ed with variable degrees of hereditary palmoplantar kera-
toderma. The association presumably relates to the ex-
pression of connexin 26 in both support cells within the
cochlea and in epidermis cells of the palms and soles[59].
GJB3 (DFNA2B)
Gap junction protein beta 3 (GJB3) gene is located on
chromosome 1p34. The gene codes for connexin 31 and
mutations result in an autosomal dominant inheritance
pattern of nonsyndromic hearing loss[57]. While recent
studies have examined functional impact of GJB3 muta-
tions, their pathogenic role in the pathogenesis of deaf-
ness remain unclear [156]. In the developing otocyst epithe-
lium of mouse, Gjb3 is expressed in various subtypes of
fibrocytes, either within the spiral limbus or along the
spiral ligament, as well as in the basilar membrane cells, in
the Reissner's membrane cells, and in subsets of the cellu-
lar elements of the cochlear ganglion[58]. Evidence exists
that mutations of GJB2 and GJB3, coding for connexin 26
and connexin 31 respectively, can interact to cause hear-
ing loss in digenic heterozygous individuals [142]. Clinical-
ly, DFNA2 presents as a postlingual, high frequency
hearing loss with onset between 20 and 40 years of age[5].
An association with auditory and peripheral neuropathies
has also been demonstrated[58]. Moreover, GJB3 muta-
tions have also been linked to erythrokeratoderma varia-
bilis without any signs of hearing impairment[91].
GJB6 (DFNB1B, DFNA3B)
The gap junction protein beta 6 gene codes for connex-
in 30 and is located on chromosome 13q12. Deficien-
cies in connexin 30 have been shown to disrupt the in-
strastrial fluid-blood barrier within the cochlear stria vas-
cularis[14]. GJB6 mutations are associated with both non-
syndromic deafness of dominant and recessive inheri-
tance phenotypes. These phenotypes may have a mono-
genic or digenic pattern, caused by mutations in GJB6 or
GJB2, or a combination of the two[18]. The autosomal domi-
nant form, DFNA3, affects middle to high frequencies
and progresses to become more severe; it can be either
pre- or postlingual [134]. The autosomal recessive form,
DFNB1, is characterized by a congenital, mild-to-pro-
found deafness without progression[36].
Ion channels
KCNQ4 (DFNA2)
The potassium voltage-gated channel, KQT-like sub-
family, member 4 gene (KCNQ4) mutations have been
reported as a cause of autosomal dominant hearing loss.
The clinical picture is similar to that produced by GJB2
mutations; characterized by a postlingual, progressive,
high-frequency hearing loss[5]. The earliest age of onset
reported in the literature is 5 years[59]. The gene is located
at chromosome 1p34 and encodes the voltage-gated po-
tassium Kv7.4 channel protein[25]. At young ages, hearing
loss in DFNA2 patients tends to be moderate and pre-
dominantly affects high frequencies. The hearing loss pro-
gresses, usually in less than 10 years, to more than 60 dB
with middle and low frequencies also involved. By the age
of 70, all affected individuals in DFNA2 families have se-
vere to profound hearing loss across all frequencies[32].
Mutations in KCNQ4 cause deafness by presumably im-
pairing cell-surface potassium channel expression [69]. A re-
cent study reports that two mechanisms, including de-
creased cell surface expression and impaired conduc-
tance of the KCNQ4 channel are underlying hearing loss
in DFNA2[32].
SLC26A4 (DFNB4)
Solute carrier family 26, member 4 gene (SLC26A4)
encodes a pendrin protein on chromosome 7q31. In the
inner ear, Pendrin functions as a chloride-iodide trans-
porter[106], thereby controlling the pH of endolymph and
allowing for proper function of certain potassium and
calcium channels. About 150 different SLC26A4 gene
mutations have been found in patients with PDS and non-
syndromic deafness (http://www.healthcare.uiowa.edu/
labs/pendredandbor//slcMutations.htm). In fact, it may
be the second most common cause of nonsyndromic he-
reditary hearing loss in the Caucasian population[3]. With-
out proper protein function, associated structural chang-
es occur in the inner ear including enlargement of the
vestibular aqueduct and of the endolymph sac[61]. These
changes are frequently seen in patients with DFNB4 and
are helpful in identifying the etiology of hearing loss.
The pattern of hearing loss in DFNB4 is prelingual and
sloping with profound high frequency hearing loss[5]. DF-
NB4 is allelic with Pendred Syndrome (congenital deaf-
ness and goiter); While individuals with Pendred syn-
drome have complete loss of chloride and iodide trans-
port, DFNB4 individuals have enough residual function
to preclude goiter formation [105].
Tight Junctions
CLDN14 (DFNB29)
The Claudin 14 gene (CLDN14) is located on 21q22.3 [38]
and encodes a tight junction protein that maintains ionic
composition of fluid at the basolateral surface of outer
hair cells[4]. CLDN14 mutations prohibit the resulting
protein from forming tight junctions, a function that is
critical for the hearing process. The absence of Claudin
10
2013 Vol.8 No.1
14 from tight junctions in the organ of Corti leads to al-
tered ionic permeability of the paracellular barrier of the
reticular lamina and that prolonged exposure of the baso-
lateral membranes of outer hair cells to high potassium
concentrations may be the cause of the death of hair
cells. Mutations at the DFNB29 locus generally produce
a typical autosomal recessive picture of hearing loss—
prelingual, bilateral, moderate to profound sensorineural
hearing loss affecting all frequencies[5].
Auditory Neuron Synapse
OTOF (DFNB9)
The Otoferlin gene (OTOF) is located on chromosome
2p23.1 [157]. The gene codes for otoferlin which is a mem-
ber of the mammalian ferlin family of membrane-an-
chored cytosolic proteins. It is thought to play a role in
the composition of ribbon synaptic vesicles and thereby
affect neurotransmitter release at the inner hair cell of co-
chlea. Mutations in OTOF cause DFNB9 recessive deaf-
ness[98]. DFNB9 presents as hearing loss that is prelin-
gual and profound [94]; this recessive hearing loss is
unique in that it may have an associated auditory neurop-
athy whereby otoacoustic emissions are normal while au-
ditory brainstem responses remain absent or grossly ab-
normal[97]. OTOF gene mutations have been inferred to
be responsible for 2-3% non-syndromic hearing losses
(NSHL) in some ethnic groups, and most of them meet
the diagnostic criteria for autosomalnonsyndromicdeaf-
ness(ANSD)[94].
PJVK (DFNB59)
The PJVK gene encodes the protein PJVK which be-
longs to the gasdermin family. The encoded protein is
found only in vertebrates and required for the proper
function of auditory pathway neurons. Defects in this
gene are a cause of DFNB59. Homozygous PJVK-mutat-
ed knock-in mice showed mimic phenotype of patients
with PJVK mutations, such as abnormal ABR and pre-
served function of IHCs (inner hair cells), and OHCs
(outer hair cells)[20]. DFNB59 was the first reported gene
that leads to deafness via neuronal dysfunction along the
auditory cascade. Several mutations have been found in
the PJVK gene [133,16].Thep.R183W mutation was found in
three Iranian families with nonsyndromic deafness due
to a neuronal defect and in a Turkish family without tran-
siently evoked otoacoustic emissions[20,16]. Haplotype
analysis did not suggest a founder effect for the Turkish
and Iranian families with the mutation. At the same posi-
tion, the p.R183Q was detected in one Chinese patient
with ANSD [119] suggesting pathogenicity of the variants.
Integral Membrane Proteins
TMC1 (DFNB7, DFNB11, DFNA36)
The transmembrane Channel-Like 1 (TMC1) gene is
located on 9q21.12 [49]. Allelic mutations may result in ei-
ther autosomal dominant or autosomal recessive nonsyn-
dromic hearing loss. The autosomal recessive loci DF-
NB7 and DFNB11 are characterized by a prelingual, pro-
found hearing loss phenotype; the autosomal dominant
allele, DFNA36 results in a postlingual progressive hear-
ing loss that initially affects high frequencies and eventu-
ally extends to all frequencies; a later onset of hearing
impairment is associated with slower progression in DF-
NA36 individuals [46]. TMC1 is a transmembrane protein
that may have a role in postnatal hair cell development
or maintenance [49], but its exact function is not known.
TMIE (DFNB6)
The transmembrane Inner Ear (TMIE) gene is also pre-
dicted to encode a transmembrane protein without a clear-
ly known function. Mutations in TMIE result in DFNB6
deafness[77]. A study of the recessive Tmie mutation in
mouse model showed shortened stereocilia of outer hair
cells, which suggests that Tmie might influence actin fil-
ament dynamics in the normal hair bundle or alternative-
ly plays a role in the organization of cytoskeleton-mem-
brane interactions in sensory hair cells [146]. Mutation in
TMIE causes an autosomal recessive prelingual deafness
that profoundly affects all frequencies[101]. The circling
mouse with TMIE gene deletion has deafness and ex-
hibit abnormal behaviors including circling and hyperac-
tivity. The hair cells in circling mice demonstrate abnor-
mal maturation and mechanotransduction [82].
Hair Cell Structure
The structure of a hair cell is largely determinant of its
ability to function properly. Thus, alterations in struc-
ture will result in various forms of hearing loss. The hair
cell structure is maintained by adhesion proteins, ciliary
proteins, as well as myosins.
CDH23 (DFNB12)
Mutations in cadherin 23 (CDH23) cause autosomal
recessive, nonsyndromic deafness DFNB12. Affected in-
dividuals present with prelingual, moderate to profound
sensorineural hearing loss (SNHL) without any vestibu-
lar impairment[12]. The DFNB12 locus maps to chromo-
some 10q21-q22[12]. It is allelic with Usher Syndrome
type 1D (profound congenital deafness, variable retinitis
pigmentosa, and variable vestibular dysfunction). The
difference between the syndromic and nonsyndromic pre-
sentation depends on the type of allelic mutation, where-
by all the nonsyndromic cases are caused by a missense
substitution [128]. The CDH23 encodes the protein cadherin
which interacts with harmonin b, a macromolecular orga-
nizer, to form a transmembrane complex that connects
11
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stereocilia into a bundle [152]. Furthermore, CDH23 inter-
acts with protocadherin 15 (PCDH15) to form tip links
that connect streocilia and control mechanoelectric trans-
duction in the inner ear [44].
Ciliary Structure
STRC (DFNB16)
The stereocilin (STRC) gene encodes the protein ste-
reocilin which is associated with the hair bundles of ste-
reocilia within the inner ear[113]. It is located on chromo-
some 15q15 and defines the autosomal recessive DF-
NB16 deafness locus [11]. Mutations in STRC result in
two possible phenotypes. A first family was reported to
have a non-progressive deafness that presented in early
childhood with moderate impairment at low and middle
frequencies and severe impairment at high frequencies [114]
whereas Verpy et al, (2001) reported a separate family with
DFNB16 deafness that had profound prelingual SNHL.
Finally, the STRC gene is thought to be a major contrib-
utor to nonsyndromic bilateral sensorineural hearing loss
(NBSNHI) among the GJB2 mutation negative pro-
bands, especially in those with mild to moderate hearing
impairment [29].
Myosins
Myosins are a family of motor proteins that hydrolyze
ATP to produce actin-based motility. There are over 30
families of myosins, each differentiated by its ATP-hy-
drolyzing domain. Within the inner ear, myosins are in-
volved in the structure and movement of stereocilia. My-
osin mutations that alter the function of stereocilia result
in sensorineural hearing loss. Mutations in MYO3A,
MYO6, MYO7A, MYO1C, and MYH9 have been re-
ported to cause nonsyndromic hearing loss.
MYO3A (DFNB30)
Myosin IIIA (MYO3A) is thought to function as a mo-
tor at the tip of stereocilia [102]. The gene has been mapped
to chromosome 10p11.1, and is responsible for the DF-
NB30 locus. Mutations in MYO3A produce a progres-
sive hearing loss, which first affects the high frequencies.
The impairment begins in the second decade and pro-
gresses over about 30 years to become severe at high and
middle frequencies and moderate at low frequencies [116].
The phenotype is thought to be inherited in an autosomal
recessive fashion, although autosomal dominant inheri-
tance with variable penetrance has not been ruled out. In
the Myo3a knockin KI/KI mice model, the unique N-ter-
minal kinase domain and a C-terminal actin-binding do-
main of MYO IIIA, which localizes to the tips of stereo-
cilia, is absent. Hearing loss, as measured by auditory
brainstem response, is reduced and progresses significant-
ly with age. Outer hair cells of Myo3a KI/KImice degener-
ate with age in a pattern consistent with their progressive
hearing loss [118].
MYO6 (DFNB37, DFNA22)
Myosin VI (MYO6) is a class of myosins that move
toward the minus end of actin filaments, in the oppsite
direction that other characterized myosins move[121]. Its
functions in the transportation of intracellular vesicles
and organelles, to facilitate the removal of molecular
components that are released by treadmilling at the taper
of the stereocilium[93,37].The MYO6 gene has been
mapped to chromosome 6q13. Mutations in MYO6
have been documented to produce both autosomal domi-
nant and autosomal recessive forms of nonsyndromic
deafness that affect all frequencies. The recessive form,
DFNB37 deafness, is congenital and profound[1], where-
as the dominant DFNA22 deafness is postlingual, late
onset, and progressive[99] and has a phenotype that mim-
ics presbycusis[80]. Additionally, mutation in MYO6 has
also been associated with familial hypertrophic cardio-
myopathy [147]. This feature may prove useful in distin-
guishing DFNA22 from other nonsyndromic autosomal
dominant hearing loss genes.
MYO7A (DFNA11, DFNB2)
Myosin VII A (MYO7A) is located on chromosome
11q12-21, designated DFNA11. A second locus (DF-
NB2) has been more within the MYO7A interval, at
11q13.5. Deafness in DFNA11 is postlingual and pro-
gressive with onset in the first to second decade of life
that affects all frequencies[55]. DFNB2 deafness can be
prelingual, progressive, and severe-to-profound or it may
have variable age of onset as a severe hearing loss[56]. In
most cases, MYO7A is associated with vestibular dys-
function, ranging from vertigo to complete absence of
vestibular function[5]. The MYO7A mutation analysis is
believed to be valid for the early diagnosis of USH1 be-
fore the appearance of visual symptoms [124]. MYO7A is
part of a functional unit, along with harmonin b and cad-
herin 23, that is essential to ensure stereocilia cohesion [6].
The syndromic and nonsyndromic forms may lie on the
same phenotype spectrum, whereby the presence of
some residual protein function results in a less severe
phenotype in nonsyndromic deafness [90].
MYO15A (DFNB3)
Myosin XVA (MYO15A) responsible for the DFNB3
locus is located on chromosome 17p11.2. MYO15A trans-
ports the protein whirlin and perhaps other molecular
components to their normal location at the stereocilia tip
for programmed elongation of the stereocilia in hair cells
of cochlea [27]. Without its proper function, affected indi-
viduals have an autosomal recessive prelingual deafness,
that may be ranked as moderate, severe or profound [129].
The shaker2 (sh2) mouse is a murine model for human
non-syndromic deafness DFNB3. In this mouse model,
12
2013 Vol.8 No.1
the BAC transgene correction confers hearing capabili-
ty, normal cochlear structure and function in 6-month-old
Myo15a mutant mice. In addition, excess Myo15a ex-
pression has no physiologically significant protective or
deleterious effects on hearing of normal mice, suggest-
ing that the dosage of Myo15a may not be problematic
for gene therapy [43].
Transcription Factors
Transcription factors are proteins that bind to DNA do-
mains and help initiate a program of increased or de-
creased gene transcription. They play important roles in
a cell’s maintenance, development, response to neigh-
boring cells, and response to the environment of the cell
The following transcription factors and/or activators
have been implicated in nonsyndromic sensorineural
hearing loss.
EYA4 (DFNA10)
Eyes absent homolog 4 (EYA4) was named for its
counterpart in Drosophilia. The human EYA4 maps to
chromosome 6q23[7] and is responsible for hearing loss at
the DFNA10 locus [120]. EYA4 is a transcriptional activa-
tor that increases the rate of gene transcription in cells of
the inner ear. Mutations in EYA4 result in an autosomal
dominant pattern of progressive deafness that begins be-
tween the ages of 20-60 and affects all frequencies. The
onset of DFNA10 deafness is later than most autosomal
dominant deafness phenotypes. Additionally, DFNA10
deafness may be associated with a dilated cardiomyopa-
thy which is unique to this phenotype [103]; the presence
of cardiomyopathy seems to correlate with EYA4 muta-
tion position [62].
POU4F3 (DFNA15)
POU4F3 is a member of the family of POU domain
transcription factors. This group of proteins shares a
POU-specific domain and a POU homeodomain, both of
which are required for high-affinity binding to DNA tar-
get sites. POU4F3 is located on chromosome 5q31 and
defines the DFNA15 locus. The target gene for POU4F3
is the Growth Factor Independent 1 (GFI1) gene [39]. Af-
fected individuals demonstrate autosomal dominant in-
heritance of progressive hearing loss. Onset is between
the ages of 15 and 30 and impairment becomes moderate
to severe across all frequencies by age 50 [154]. It should
be noted, however, that some cases have shown a highly
variable phenotypic profile with respect to onset, pro-
gression, and affected frequencies[15,31,149]. Full penetrance
has been documented for this gene mutation.
POU3F4 (DFNX2)
POU domain 3 factor 4 (POU3F4) is a transcription
factor gene responsible for an X-linked pattern of deaf-
ness, known as DFNX2 deafness[26]. The POU3F4 gene
is located on chromosome Xq21.1[24]. Affected individu-
als have a characteristic computerized tomography (CT)
appearance of a dilated internal auditory canal along
with temporal bone abnormalities that can range in sever-
ity. Regardless, the sensorineural component progresses
over time and the deafness may present alongside vestib-
ular dysfunction [115].
Cytokinesis
DIAPH1 (DFNA1)
Diaphenous homolog 1 (DIAPH1) gene mutations is
known to cause an autosomal dominant, progressive,
postlingual DFNA1 sensorineural hearing loss (SNHL)
that begins with increased thresholds at low frequencies
and progresses to involve all frequencies [51]. The hear-
ing loss begins around the age of 10 and progresses to
profound deafness by age of 30. The gene locus has been
mapped to 5q31 [139]. DIAPH1 belongs to the formin fami-
ly of proteins. It is believed to be involved in cytokinesis
and establishment of cell polarity and is a profilin ligand
and target of Rho that regulates polymerization of actin,
the major component of the cytoskeleton of hair cells of
the cochlea [60], and it is thus thought to be essential to
the structure and function of the stereocilia. Although it
is expressed in many tissues, DFNA1 individuals do not
have any other symptoms or any vestibular dysfunction.
ESPN
The ESPN (ESPN) codes for the Espin protein,which
is believed to function in the growth and maintenance of
stereocilia and has a potent actin bundling activity in the
inner ear [23]. It maps to chromosome 1p36.31-36.11 and
defines the autosomal recessive DFNB36 deafness locus.
Affected individuals have a prelingual, profound hear-
ing impairment associated with vestibular areflexia [78].
Boulouiz et al. (2008) showed that mutations in the ES-
PN gene could cause recessive nonsyndromic deafness
without vestibular areflexia.
The vestibular dysfunction may or may not be symp-
tomatic. However, if areflexia is confirmed then it be-
comes helpful in narrowing the differential of which
deafness genes may be involved in the pathology. ESPN
mutations have also been shown in individuals with auto-
somal dominant nonsyndromic hearing loss without any
vestibular involvement[23]. Boulouiz et al. (2008) mapped
the disease locus in a large consanguineous ARNSHL
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family from Morocco by genome-wide linkage analysis
to the DFNB36 locus and a recessive ESPN mutation
causing congenital hearing loss, but without vestibular
dysfunction.
Extracellular Matrix Proteins
The extracellular matrix (ECM) of the auditory sys-
tem optimizes the propagation and detection of sound
within the Cochlea. It is especially important for the tec-
torial and basilar membrane which physically move as
auditory stimuli are transmitted. Changes in the ECM
may affect these membranes resulting in sensorineural
hearing loss.
COL11A2 (DFNA13, DFNB53)
Mutationin thecollagentype11alpha2gene(COL11A2)
results in autosomal dominant hearing loss at the DF-
NA13 locus [68] located on chromosome 6p21.3[9]. It is al-
lelic with Stickler syndrome, i.e. short stature, myopia,
arthropathy, mid-face hypoplasia along with high fre-
quency progressive sensorineural hearing loss. In con-
trast to Stickler syndrome, DFNA13 is a postlingual
mid-frequency hearing loss that begins at age 20-40
years and does not progress beyond presbycusis [29,68].
Thus the audiogram of affected individuals is initially
U-shaped (‘cookie-bite’) and eventually flattens with
presbycusis[48]Mutation in COL11A2 can also cause auto-
somal recessive non-syndromic hearing loss at the DF-
NB53 locus, characterized by a prelingual, profound,
non-progressive hearing loss phenotype[13]. COL11A2
codes for collagen fibrils that form the structure of the
tectorial membrane [68]. Many collagen diseases are asso-
ciated with hearing loss, so it may be that nonsyndromic
hearing loss is simply the mildest phenotype associated
with mutations in COL11A2.
COCH (DFNA9)
The coagulant factor C homolog (COCH) gene, mapped
to chromosome 14q12-13, is associated with the DFNA9
locus [65]. It is inherited in an autosomal dominant fash-
ion and presents as postlingual, progressive hearing loss,
beginning at high frequencies and progressing over 10-20
years to profound hearing loss at all frequencies [126]. Age
of onset varies from 20 to 60 years [65,126]. The earliest re-
ported age of onset is two years. The clinical sequence
has started in the child with a vestibular dysfunction: re-
current rotatory dizziness during 12 months. And At the
age of 3, he developed sensorineural hearing loss on both
sides [145]. Individuals with DFNA9 deafness also have
vestibular dysfunction similar to Meniere’s disease [31].
Patients often self report the vestibular disturbances [153],
which becomes helpful in identifying this type of non-
syndromic hearing loss. A new study describes newly
discovered extralabyrinthine findings within the middle
ear in DFNA9 and discusses their implications [144].
COCH encodes the protein cochlin, which is abundant-
ly expressed both in the cochlea and in the vestibular lab-
yrinth [92]. Cochlin is likely synthesized in the endoplas-
mic reticulum and secreted into the extracellular space
where it plays an integral part in mediating interactions
among proteins. Mutations in COCH may disrupt these
protein interactions thereby altering the function of the
extracellular matrix.DFNA9 may not be caused by haplo-
insufficiency of COCH, rather a gain-of-function or dom-
inant-negative mutation [63].
TECTA (DFNA12, DFNB21)
Mutations in the alpha tectorin (TECTA) gene cause
hearing loss that is unique because it is a form of autoso-
mal-dominant, congenital hearing loss. Typically autoso-
mal-dominant hearing impairment is not present at birth
but TECTA is the exception. TECTA mutations produce
moderate to severe, nonprogressive hearing loss affect-
ing predominantly middle frequencies[45]. The phenotype
is linked to loci DFNA12 at chromosome 11q22-24 [155].
An autosomal recessive form of deafness has also been
linked to TECTA at the DFNB21 locus [148]. It presents as
prelingual, severe hearing loss with a flat or U-shaped
audiogram [76]. This audiometric profile is easily recog-
nizable among families with autosomal recessive, non-
syndromic hearing impairment due to the dip in the mid-
dle frequencies. A study for the prevalence of hearing
loss caused by TECTA mutations has been investigated
in Japanese families with autosomal dominant hearing
loss. TECTA mutations were detected in 2.9% (4/139) of
those families[75].
The TECTA gene encodes a major non-collagenous
component of the tectorial membrane called alpha tecto-
rin. Alpha tectorin bridges the stereocilia bundles of the
hair cells [140], allowing them to move in unison. Ulti-
mately, mutations in TECTA disrupt sound transmission
to the stereocilia.
Mitochondrial Deafness
Mitochondria are intracellular organelles that not only
produce cellular energy in the form of ATP, but also con-
tribute to cell-mediated death, or apoptosis, and are im-
plicated in preventing cell damage by reactive oxygen
species. Mitochondria harbor their own DNA that is in-
herited maternally and encodes proteins necessary for
their structure and function. Mutations in mitochondrial
DNA (mtDNA) cause a variety of systemic disorders in-
cluding syndromic hearing loss; additionally, a number
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of mtDNA mutations have been identified which result
in nonsyndromic sensorineural hearing loss. In particu-
lar, mutations in two genes, MTRNR1 and MTTS1, have
been commonly found to result in nonsyndromic deaf-
ness.
MTRNR1
MTRNR1 encodes for the 12s ribosomal RNA (rRNA).
Mutations in this gene result in a maternally inherited
nonsyndromic hearing loss that is often provoked or made
worse by exposure to aminoglycoside antibiotics [86]. Cer-
tain mutations in MTRNR1 may cause tighter binding to
aminoglycosides causing hypersensitivity to the antiobi-
otic that become toxic to hair cells [40]. There is also evi-
dence for the fact that in individuals with an MTRNR1 mu-
tation, aminoglycoside reduce mitochondrial protein syn-
thesis precluding normal cellular function [137].
The most common mutation in MTRNR1 is the
A1555G mutation. This mutation has been found in
many families with maternally-inherited hearing loss as
well as in individuals with aminoglycoside-induced hear-
ing loss. Penetrance can be variable[10]; low penetrance
has been specifically reported among the Chinese popula-
tion [17]. Because of the variable penetrance, a range of
phenotypes from normal hearing to profound deagness
exist and imply the presence of a nuclear modifier [54,142].
In 2006, tRNA 5-methylaminomthyl-2-thiouridylate
methyltransferase (TRMU) was identified as the modifier
gene[35]. When mutated, TRMU alters the phenotypic ex-
pression of the A1555G mutation in MTRNR1. This
may be due to variable exposure to aminoglycosides be-
tween family members. In fact, age of onset also varies,
in which case the onset of deafness in exposed individu-
als is younger [136]. Moreover, associated symptoms have
occasionally been linked to A1555G-related hearing loss,
including Parkinson Disease and cardiomyopathy [100].
Nonetheless, the majority of cases are nonsyndromic.
MTTS1
The MTTS1 gene encodes the mitochondrial tRNA for
serine (UCN) (tRNASer(UCN)). Several nonsyndromic
progressive hearing loss causing mutations have been
identified in MTTS1. Similarly to mutations in MTRNR1,
penetrance due to MTSS1 mutation varies greatly both
within and between families. Additionally, certain muta-
tions can cause associated features; the A7445G mutation
has been associated with palmarplantar keratoderma [89]
and the 7472insC mutation has been linked to dysarthria,
ataxia, myoclonus, and cognitive impairment[41]. Muta-
tions in MTTS1 have also been shown to induce amino-
glycoside hypersensitivity as seen with MTRNR1 muta-
tions[42]. In essence, due the relationship to aminglyco-
side antibiotics, a role of the screening of mitochondrial
mutations in families with maternally-inherited sensori-
neural hearing loss is warranted.
Other/Unknown Function
TMPRSS3 (DFNB8, DFNB10)
Mutations in transmembrane protease, serine 3 (TM-
PRSS3) are associated with two loci that can be differen-
tiated by phenotype. DFNB8 begins in childhood (age
10 to 12) and rapidly progresses over 5 year to profound
deafness across all frequencies [151]; DFNB10 on the other
hand is typically present at birth as severe SNHL but in-
dividuals can present as late as 6 or 7 years of age [67]. The
TMPRSS3 gene is located on chromosome 21q22 [151].
TMPRSS3 is mainly expressed in the spiral ganglion
neurons and is involved in the process of aminoglyco-
side antibiotics induced deafness [150]. It has also been sug-
gested that lack of Tmprss3 leads to a decrease in Kcnma1
potassium channels expression in inner hair cells [73].
WFS1 (DFNA6/14/38)
Defects in the Wolfram syndrome 1 gene (WFS1) is one
of only two genes that lead to a nonsyndromic, autoso-
mal dominant low frequency sensorineural hearing loss.
Mutations in WFS1 have been linked to DFNA6, DF-
NA14 and the DFNA38 locus. Other than DFNA1, the
WFSI loci DFNA6/14 can be singled out by its S-shaped
pure tone audiogram [125]. DFNA6/14/38 deafness has
minimal progression, consistent with changes of presby-
cusis. This can be contrasted with DFNA1 which has a
rapid progression[60]. Furthermore, the onset of DFNA14/
6/38 is in childhood, from 5 to 15 years of age [132]. WFS1
is located on chromosome 4p16[111]. It codes for an extra-
cellular matrix-integral glycoprotein of endoplasmic retic-
ulum, suggesting thus a role in membrane trafficking, pro-
tein processing and regulation of endoplasmatic reticu-
lum calcium homeostasis [112]. WFS1 mutations are also
responsible for a syndromic form of hearing loss, Wol-
fram syndrome, defined by diabetes insipidus, diabetes
mellitus, optic atrophy, and sensorineural deafness. The
unique collection of audiometric data from genotyped
Wolfram syndrome patients shows no substantial pro-
gression in sensorineural hearing impairment with ad-
vancing age, no relation to the types of WFS1 mutations
identified, and no significant sex-related differences [87].
PCDH15 (DFNB23)
The protocadherin 15 (PCDH15) gene on chromo-
some 10q21.1is responsible for DFNB23. PCDH15 inter-
acts with cadherin 23 to form tip links of stereocilia [44].
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Missense mutations in PCDH15 have been found to
cause DFNB23. It has a classic autosomal recessive hear-
ing loss phenotype that is a prelingual severe to pro-
found sensorineural deafness. The gene is allelic with
Usher Syndrome 1F, caused by more severe mutations
(splicing, frameshift, nonsense, large deletions) produc-
ing a syndromic phenotype which also involves visual
impairment [1].
USH1C (DFNB18)
Mutations in the Usher Syndrome 1C (USH1C) gene
can also lead either to a syndromic or a nonsyndromic
phenotype depending on the severity of the mutation.
The nonsyndromic phenotype, DFNB18, is a prelingual
profound deafness. Usher 1C syndrome not only has
profound prelingual deafness, but also retinitis pigmento-
sa and vestibular areflexia [81]. Both phenotypes are in-
herited in an autosomal recessive fashion. The USH1C
gene is located on chromosome11p14.3, and codes for
the protein harmonin, a PDZ domain protein that forms a
complex with CDH23 to bundle stereocilia [152].
WHRN (DFNB31)
Mutations in the whirlin (WHRN) gene, mapped on
9q32-q34 is responsible for prelingual profound deaf-
ness (DFNB31) [72]. Whirlin encoded by the WHRN gene
is known to interact with MYO15A for stereocilia mor-
phogenesis [130]. Mouse studies show that WHRN is in-
volved directly in actin filament packing that is neces-
sary for the elongation of sterocilia after birth[71]. While
Myosin XV may interact with other proteins, Whirlin is
important for hair cell maturation[72]. WHRN mutations
may also cause Usher Syndrome type 2D (USH2D) which
presents with deafness, retinitis pigmentosa, but normal
vestibular function. Mutations to the long isoform are
believed to cause the syndromic manifestations [135].
Genomic Advances for Molecular Testing
and Gene Discovery in Hereditary Hear-
ing Loss
Testing for mutations responsible for the most com-
mon forms of syndromic and non-syndromic hearing
loss plus congenital CMV infection can determine the
cause of hearing loss in most cases. Approximately
15%-25% of congenital hearing loss cases in children
are due to Cytomegalovirus (CMV) infections. Early iden-
tification of deafness allows for appropriate intervention
or rehabilitation that has lifelong implications for lan-
guage development. The lifetime societal costs for child-
hood hearing loss are estimated at $1.1 million (http://
www.audiologyonline.com). With over 90% of babies
currently being screened for hearing loss at birth in the U.
S. and given the recommendations to incorporate genetic
testing as part of expanded Early Hearing Detection and
Intervention (EHDI) programs, the Joint Committee on
Infant Hearing (JCIH) endorses early detection of and in-
tervention for infants with hearing loss through integrat-
ed, interdisciplinary community, state, and federal sys-
tems of universal newborn hearing screening. Further-
more, since several hundred genes are involved in the bi-
ology of hearing loss and additional genes and mutations
may yet be identified, newer platform technologies for
high-throughput genetic testing should make diagnostic
testing for hearing loss more flexible, less expensive,
and more comprehensive while being as sensitive.
Arrayed Primer Extension Microarray for Detec-
tion of Known Deafness-Associated Mutations
Microarray approaches have been used extensively for
analyzing the expression levels of thousands of genes
and for performing multiplex genotyping of single nucle-
otide polymorphisms (SNPs) and large-scale mutation
screening. The DNA microarray, or biochip, is a hybrid-
ization-based genotyping technique that offers simultane-
ous analysis of many genetic mutations. Several studies
using microarray diagnostics for high-throughput, com-
prehensive, and cost-effective molecular screening of
mutations of deafness genes have demonstrated accurate
and reliable results[108,33,] http://www.asperbio.com/HHL.
htm. The HHL APEX (Hereditary Hearing Loss Arrayed
Primer Extension) microarray based on APEX designs [50]
was the first hearing loss diagnostic panel using this
strategy. APEX array technology allows the simultane-
ous analysis of multiple mutations through hybridization
of fragmented template DNA to specifically designed
primers, followed by single nucleotide extension at the
site of each mutation. The HHL APEX array enables
analysis of 198 mutations across eight genes (GJB2,
GJB6, GJB3, GJA1, SLC26A4, SLC26A5, MTRNR1
and MTTS1) most commonly associated with non-syn-
dromic sensorineural hearing loss, in a single test. All
known mutations for each of the 8 genes are included on
the APEX microarray at the time of its design. However,
novel mutations continue to be identified and thus lack
of identification of mutations on the HHL array, there-
fore, does not necessarily exclude a gene as the cause of
the hearing loss. Hence, targeted diagnostic sequencing
still remains a follow-up tool to screening with the
APEX assay, for patients in whom a single pathogenic
mutation was identified in a gene on the array. Further-
more, since the APEX panel is comprised of a limited
number of genes and sequence variants, it may also not
accurately represent the most frequent hearing loss al-
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leles in a given test population. Together, the current
APEX array configuration adds little diagnostic value
for patients with no mutations in the GJB2 and/or GJB6
genes [95]. The mutations on the APEX array do not sub-
stantially contribute to age-related hearing loss either [96].
Li et al (2008) combined allele-specific PCR and uni-
versal array methodologies for the detection of muta-
tions causing hereditary hearing loss. The approach
termed multiplex allele-specific PCR-based universal ar-
ray (ASPUA) allows for simultaneous screening of 11
mutations in 3 genes. These include GJB2 (c.35delG,
c.167delT, c.176_191del16, c.235delC, c.299_300delAT),
GJB3 (c.538C>T; p.Arg180X, c.547G>A; p.Glu183Lys)
and SLC26A4 (c.707T>C; p.Leu236 Pro, c.2168A>G; p.
His723Arg, c.919-2A>G; Splice acceptor). The ASPUA
universal array makes the multiplex detection flexible,
as the numbers of mutations detected can be increased
and the microarray could also be redesigned with a great-
er number of subarrays so that much larger numbers of
patient samples could be tested.
High-Throughput Detection of Deafness Caus-
ing Mutations Using Resequencing Microarrays
Two high-throughput resequencing Affymetrix arrays
capable of resequencing 13 genes involved in sensorineu-
ral hearing loss (SNHL) (GJB2, GJB6, CDH23, KCNE1,
KCNQ1, MYO7A, OTOF, PDS, MYO6, SLC26A5,
TMIE, TMPRSS3, USH1C) were developed by research
groups from Harvard and from Cincinnati [47]. This oli-
go-hybridization array-based sequencing methodology
was used in the design of OtoChipTM Test for hearing
loss and Usher Syndrome now available at Harvard Med-
ical School. The current format of OtoChipTM contains
a DNA sequence of 2750 base pairs encompassing 19
genes [http://pcpgm.partners.org/lmm/tests/hearing-loss/
Otochip].
The HHL APEX array can only detect specific known
hearing loss mutations whereas the Affymetrix rese-
quencing arrays allow for the discovery of new muta-
tions. However, resequencing arrays do not have high
sensitivity for detection of small deletions and inser-
tions, which constitute ~24% of disease-causing muta-
tions in the Human Gene Mutation Database [47].
Comprehensive Genetic Testing for Hearing LO-
oss Using Targeted Enrichment and Massively
Parallele Sequencing.
OtoSCOPE, a comprehensive genetic screen for deaf-
ness, was developed at the University of Iowa [107]. This
diagnostic platform uses targeted capture and massively
parallel sequencing to provide direct sequencing of the
66 genes known to cause NSHL. Usher syndrome and
Pendred syndrome genes are also included [http://www.
morl-otoscope.org]. OtoSCOPE offers relatively high
specificity and sensitivity. However, its greatest limita-
tion is that repetitive regions cannot be captured. Anoth-
er clinical assay, testing 84 human genes involved in
both syndromic HL and NSHL, is also available from
Otogenetics [http://www.otogenetics.com/].
Next Generation Sequencing to Identify Genes
for Hereditary Hearing Loss.
Now, the relatively low cost and rapid technological
advances in next generation sequencing (NGS) technolo-
gies are dramatically changing our ability to identify
genes and disease-causing mutations. Because of the ge-
netic heterogeneity of hearing loss, targeted DNA cap-
ture and massively parallel sequencing are ideal tools to
address this challenge. These new sequencing technolo-
gies replace the one small-template-at-a-time paradigm
of Sanger sequencing with‘massively parallel’sequenc-
ing of millions of small fragments covering the whole ge-
nome as well as individual regions with great redundan-
cy. The basic methodological steps of NGS include: a) tem-
plate preparation, using methods ranging from pyrose-
quencing and sequencing by ligation to reversible dye
termination and real-time single molecule sequencing; b)
massive sequencing and imaging, and c) data analysis [64,70].
The NGS market is rapidly evolving with a large number
of developments taking place to increase accuracy and
speed, and reduce costs of sequencing. Several NGS plat-
forms are now available, including the 454 GS FLX
(Roche), SOLiD (Life Technologies) and the HiSeq se-
ries (Illumina). More recently,“bench-top”DNA se-
quencing instrumentation such as 454 GS Jr (Roche),
MiSeq (Illumina) and IonTorrent Personal Genome Ma-
chine (PGM) from Life technologies have also been re-
leased, capable of sequencing in a matter of days.
Several studies have used a combination of targeted
capture and NGS technology to identify deafness genes.
Targeted genomic capture is performed on the linked re-
gion identified previously by genetic analysis followed
by sequencing of the chromosomal region. On a larger
scale, whole exome sequencing is extremely promising,
as it screens the exons of all genes by capturing and se-
quencing the 1% of the human genome that codes for
protein. Several Human Exome Sequence Capture kits
are now available allowing library preparation with sub-
sequent exome enrichment. These include the Agilent
SureSelect Human All Exon Kit, the Illumina TruSeq
Exome Enrichment Kit, the TargetSeq in-solution target
enrichment kit from Life Tech/Applied Biosystems and
SeqCap EZ Exome from Roche NimbleGen. Both specif-
ic genomic regions capture and whole exomes sequenc-
ing have been successful at identifying genes for both
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non-syndromic and syndromic hearing loss (Table 3).
Obstacles and challenges still remain, but the field is
changing at a dramatic pace, making deafness gene dis-
covery faster and more efficient and screening for genet-
ic hearing loss more comprehensive.
Conclusion
A thorough evaluation of patients with nonsyndromic
deafness is warranted in order to provide accurate treat-
ment goals and may be beneficial for the future applica-
tion of gene therapy in hearing loss. As can be seen, mu-
tations in most nonsyndromic deafness genes present a
classical clinical feature dependent on inheritance pat-
tern. Autosomal recessive inheritance often implies a
prelingual, severe deafness, whereas autosomal domi-
nant inheritance implies postlingual onset and variable
severity. There are some exceptions, however, for in-
stance, mutations in MYO7A, TMPRSS3, and STRC are
inherited recessively, but onset is postlingual. On the
other hand, some dominantly inherited loci, like DFNA8/
12, have prelingual onset. Mutations associated with lo-
ci DFNA12, DFNA13, and DFNA21, affect the middle
frequencies thereby producing a U-shaped audiogram.
Some defects, as exemplified by mutations in the
POU3F4 gene, cause characteristic changes on imaging
that can be identified. Other genes have associated ves-
tibular dysfunction and therefore can be filtered to nar-
row the etiology by this symptom. Table 2 highlights
unique features of certain nonsyndromic hearing impair-
ment genes. By performing a proper family tree of inher-
itance and evaluating the patient, it may be possible to at
least narrow down the myriad of nonsyndromic genes in-
to a workable differential. In the future, this may be a
key to successful therapy, gene-based or otherwise.
Identifying genes causing non-syndromic hearing loss
has been challenging in terms of discovering its cause
and deciphering the mechanisms underlying it. Until re-
cently, its extreme genetic heterogeneity precluded com-
prehensive genetic testing and large-scale population
screening. NGS appears ideally suited to address this
challenge. Several studies have already shown that the
use of NGS technology holds promises as a tool for
screening congenital deafness genes. The availability of
a more comprehensive diagnostic test compared to the in-
dividual“gene by gene”analysis approach, will provide
better opportunities to identify the deafness causing mu-
tation in patients, permitting thus prompt management
and improved genetic counseling. With high-throughput
sequencing still evolving, many questions remain to be
addressed before implementing it in routine clinical use.
A myriad of ethical issues have to be sorted and there is
a need for standard laboratory procedures and regula-
tions for quality control, data analysis and validation.
Nevertheless, initial findings of these advanced technolo-
gies for gene discovery and detection of deafness-caus-
ing mutations hold great promise for solving the major
portion of genetic deafness
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